Rybelsus and Ozempic tablets explained

Rybelsus and Ozempic tablets are oral semaglutide: once-daily tablets for adults with type 2 diabetes, covered by one shared FDA label. They come in different strengths, and the label says they “are not substitutable on a mg-to-mg basis,” so a Rybelsus number and an Ozempic tablet number never mean the same thing.

Tablets come in fixed strengths, so there’s nothing to measure; syringe math only applies to injections drawn from a vial (that’s what the semaglutide units calculator is for). The weekly Ozempic injection is a different product with its own label and its own missed-dose rule.

What the label covers

The label is titled “RYBELSUS (semaglutide) tablets, for oral use” and “OZEMPIC (semaglutide) tablets, for oral use.” Both products sit on the same FDA application, NDA 213051, first approved on September 20, 2019 (Drugs@FDA).

As of October 16, 2026, the label says they’re indicated:

• “as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus”; and
• “to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.”

The indications section was last revised in October 2025, and Drugs@FDA lists a new-indication supplement dated October 17, 2025 (label, section 1; Drugs@FDA). Neither tablet is labeled for weight reduction; that’s Wegovy tablets, a separate product covered in the Wegovy pill guide.

The two tablets side by side

Source: the Rybelsus and Ozempic tablets label, sections 2.2, 3 and 12.3, checked October 16, 2026.

The bioavailability row explains the odd numbers. Only a small share of a semaglutide tablet reaches the blood, and Ozempic tablets deliver a larger share than Rybelsus. The label says there were “no clinically significant differences” in average steady-state exposure between 3, 7 and 14 mg of Rybelsus and 1.5, 4 and 9 mg of Ozempic tablets, “respectively.” So Rybelsus 7 mg lines up with Ozempic tablets 4 mg, not 7 mg. Steady-state exposure was reached after 4 to 5 weeks of daily tablets (section 12.3).

Not substitutable mg for mg

The label’s own words: “RYBELSUS and OZEMPIC tablets are not substitutable on a mg-to-mg basis.” For switching between the two, it says:

• “Do not switch between RYBELSUS and OZEMPIC tablets during the initiation phase (Days 1 to 30).”
• After day 30, its Table 1 pairs Rybelsus 7 mg with Ozempic tablets 4 mg, and Rybelsus 14 mg with Ozempic tablets 9 mg.
• Start the other product “the day after discontinuing the previous semaglutide tablet product.”

That’s a prescriber’s decision, not a swap to make on your own (label, sections 2.1 and 2.3).

Wegovy tablets are a different product. They come in 1.5, 4, 9 and 25 mg, so some numbers match Ozempic tablets, but they have their own label and their own uses. The Wegovy label says using Wegovy “with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended” (Wegovy label, sections 1 and 3). Neither label gives a way to switch between Wegovy tablets and Rybelsus or Ozempic tablets; only your prescriber can manage a change like that. See the Wegovy pill for that label.

How to take them

The label gives the same rules for both tablets (label, section 2.1):

1. Take it first thing, on an empty stomach

   “Take one RYBELSUS or OZEMPIC tablet orally once daily on an empty stomach in the morning.”

2. Use a little plain water

   Take it “with water (up to 4 ounces of water).” The label says not to take it “with other liquids besides water.”

3. Swallow it whole

   “Swallow tablets whole. Do not split, crush, chew or dissolve in any solution.” And “Do not take more than one tablet per day.”

4. Wait 30 minutes

   “Wait at least 30 minutes before eating food, drinking beverages or taking other oral medications.”

Keep the tablets in their original bottle until you take one, “to protect tablets from moisture,” at 20°C to 25°C (68°F to 77°F), with excursions allowed from 15°C to 30°C (59°F to 86°F) (section 16).

If you miss a tablet

“If a dose is missed, skip the missed dose and take the next dose the following day” (label, section 2.1). There’s no catch-up window and no doubling: the label also says not to take more than one tablet a day.

That’s different from the weekly Ozempic injection, which you may take late “within 5 days after the missed dose” (Ozempic injection label, section 2.1). The missed GLP-1 dose guide compares every label’s rule.

The schedule as labeled

These are the label’s words, quoted for reference. Follow your prescriber: they choose your dose and when it changes (label, section 2.2).

• Rybelsus: days 1 to 30, “3 mg orally once daily (this dosage is not effective for glycemic control).” Days 31 to 60, “increase the dosage to 7 mg.” On day 61 or later, stay at 7 mg if no more glycemic control is needed, or “increase the dosage to 14 mg orally once daily” if it is.
• Ozempic tablets: days 1 through 30, “1.5 mg orally once daily (this dosage is not effective for glycemic control).” Days 31 to 60, “increase the dosage to 4 mg.” On day 61 or later, stay at 4 mg, or “increase the dosage to 9 mg orally once daily” if more glycemic control is needed.

The label also covers moving from the injection. “Patients taking the 0.5 mg dose of OZEMPIC injection may switch to RYBELSUS tablets,” starting “one week after discontinuing” the injection, at 7 mg or 14 mg of Rybelsus, or 4 mg or 9 mg of Ozempic tablets (section 2.4). Your prescriber decides whether and how.

The trial evidence

The label reports these trials (label, section 14):

The PIONEER 6 and SOUL papers state Novo Nordisk funding (PIONEER 6, SOUL).

Two limits worth knowing. PIONEER 6 showed that oral semaglutide’s cardiovascular risk “was not inferior to that of placebo”; it didn’t establish a lower risk (PIONEER 6). In SOUL, cardiovascular death alone wasn’t clearly different (6.2% vs 6.6% on placebo, hazard ratio 0.93, 95% CI 0.8 to 1.09), and the paper says its confirmatory secondary outcomes “did not differ significantly between the two groups” (SOUL).

Safety on the label

Boxed warning. The label carries a boxed warning about thyroid C-cell tumors seen in rodents. The tablets must not be used by people with “a personal or family history of medullary thyroid carcinoma (MTC)” or with “Multiple Endocrine Neoplasia syndrome type 2 (MEN 2),” or after a prior serious allergic reaction to semaglutide or any ingredient (section 4).

Common side effects. The label lists “nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation” as the most common. In its placebo-controlled pool:

Gastrointestinal side effects overall were reported by 41% on 14 mg, 32% on 7 mg and 21% on placebo, and “the majority of reports of nausea, vomiting and/or diarrhea occurred during dose escalation.” The Medication Guide puts it plainly: nausea, vomiting and diarrhea “are most common when you first start” (label, section 6 and Medication Guide).

Pregnancy. “Discontinue RYBELSUS or OZEMPIC tablets in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide” (section 8.3). Semaglutide stays in the blood for about five weeks after the last tablet; see how long Ozempic stays in your system.

Questions people ask